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ABSTRACT
Objectives To assess the quantity and evaluate the 
quality of policies and curricula focusing on conflicts of 
interests (COI) at medical schools across Germany.
Design Cross- sectional study, survey of medical schools, 
standardised web search.
Setting Medical schools, Germany.
Participants 38 German medical schools.
Interventions We collected relevant COI policies, 
including teaching activities, by conducting a search of 
the websites of all 38 German medical schools using 
standardised keywords for COI policies and teaching. 
Further, we surveyed all medical schools’ dean’s offices. 
Finally, we adapted a scoring system for results we 
obtained with 13 categories based on prior similar studies.
Main outcomes and measures Presence or absence 
of COI- related policies, including teaching activities 
at medical school. The secondary outcome was the 
achieved score on a scale from 0 to 26, with high scores 
representing restrictive policies and sufficient teaching 
activities.
Results We identified relevant policies for one medical 
school via the web search. The response rate of the 
deans’ survey was 16 of 38 (42.1%). In total, we identified 
COI- related policies for 2 of 38 (5.3%) German medical 
schools, yet no policy was sufficient to address all COI- 
related categories that were assessed in this study. The 
maximum score achieved was 12 of 26. 36 (94.7%) 
schools scored 0. No medical school reported curricular 
teaching on COI.
Conclusions Our results indicate a low level of action 
by medical schools to protect students from undue 
commercial influence. No participating dean was aware 
of any curriculum or instruction on COI at the respective 
school and only two schools had policies in place. The 
German Medical Students Association and international 
counterparts have called for a stronger focus on COI in the 
classroom. We conclude that for German medical schools, 
there is still a long way to go.
INTRODUCTION
Contacts between the pharmaceutical or 
medical device industry and healthcare 
professionals have long been a point of 
discussion, as they may lead to conflicts of 
interest (COI). According to the widely 
accepted definition from the Institute of 
Medicine, COI are circumstances that create 
a risk that professional judgements or actions 
regarding a primary interest will be unduly 
influenced by a secondary interest.1 In 
healthcare COI may exist between the physi-
cian’s commitment to patient care and indus-
try’s interest in selling their products. There 
is mounting evidence indicating an adverse 
effect of pharmaceutical promotion on physi-
cians’ prescribing behaviour.2 Patients may 
suffer from the consequences directly due to 
exposure to unnecessary risks as well as indi-
rectly through a higher financial burden for 
healthcare systems.2 Simultaneously, univer-
sities and medical schools, in particular, are 
increasingly expected to conduct transla-
tional research from ‘bench to bedside’—a 
paradigm that includes market commercial-
isation and requires industry collaborations 
which makes contact with the private sector 
inevitable. Therefore, COI present challenges 
towards medical professionalism.3
Strengths and limitations of this study
 ► This study is the first standardised qualitative anal-
ysis of medical school conflict of interest (COI) poli-
cies in Germany.
 ► The cross- sectional study comprises structured web 
searches and surveys of deans’ offices.
 ► The study design is based on previous studies in 
other countries and therefore allows for internation-
al comparison.
 ► Despite combining multiple approaches of data col-
lection, teaching activities and policies may have 
been missed.
 ► Since this study focused on COI policies that apply to 
the specific setting of medical schools, other state or 
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In order to protect independent patient care, profes-
sional handling of COI by physicians is essential. It has 
been argued, that physicians’ attitudes towards the phar-
maceutical industry and their inclination to be influ-
enced by marketing efforts manifest early during their 
professional training.3 A large body of evidence exists 
showing that medical students themselves are in contact 
with industrial companies on a regular basis.3–11 Contacts 
increase in the course of studies, with more interactions 
during the clinical part of their studies.4 12 13 A study by 
Lieb and Koch7 at eight German medical schools revealed 
that only 12% of surveyed students had never received 
a gift or attended a sponsored event. The authors also 
report that 60% of these students had a promotional 
gift handed on to them by a physician they worked with, 
who received the gift by a company beforehand.7 Profes-
sors and other physicians act as role models students 
base their attitudes and actions on—not only regarding 
their clinical work, but also regarding interactions with 
industry and COI. The actions of those role models 
constitute a ‘hidden curriculum’ and conceptualise 
what is perceived to be normal.14 The extent to which 
teaching faculty in Germany has financial ties to industry 
actors remains largely unclear. Despite frequent debates, 
there is currently no German equivalent to the Physician 
Payments Sunshine Act in USA, where information on 
payments from industry to physicians is collected, catego-
rised and made publicly available by law.15 Data reported 
by the German nonprofit investigative journalism news-
room CORRECTIV based on voluntary disclosures indi-
cate that physicians, pharmacists and other healthcare 
professionals together with their respective institutions 
received a minimum of 562 million euro in 2016 alone.16 
How many of these providers had teaching responsibil-
ities at medical schools is largely unknown. Such rela-
tionships may affect academic and publishing interests, 
the content faculty chooses to disseminate to medical 
students and their general professional medical opin-
ions.17 18 Overall, COI of teaching staff are not commonly 
disclosed to medical students in Germany.
Previous studies report that 65% of surveyed medical 
students in Germany felt inadequately prepared for 
interactions with the pharmaceutical industry.19 90% of 
those students in Germany reported that dealing with 
industrial marketing practices had never been addressed 
during their lectures.19 In another survey, 14.4% of the 
participating German medical students noted that they 
attended a lecture or courses dealing with COI; of those 
classes, however, 90% were optional.20 Altogether, it 
remains unclear to what extent German medical schools 
include COI topics in their curricula. Aside from teaching 
about industry practices of marketing and promotion, 
restrictive COI policies at the medical school level have 
been suggested to increase students’ awareness of the 
consequences of inappropriate marketing practices in 
the learning environment.21 Some studies indicate that 
COI policies at medical schools have a significant impact 
on prescribing practices by inoculating physicians against 
persuasive aspects of pharmaceutical promotion.22–24 In 
Germany, Lieb and Koch found that in 2013 only two out 
of 36 medical schools reported having a COI policy.20 
However, none of these schools reporting a policy (TU 
Dresden and RWTH Aachen) supplied the policies them-
selves and hence, the content and strength of the policies 
remain unclear. The objective of this study was to deter-
mine whether medical schools in Germany have institu-
tional COI policies in place and to assess the strength of 
the policies obtained by means of 13 predefined criteria 
including the existence of teaching activities.
METHODS
Our methodology built on criteria used in earlier studies 
on COI policies such as the American Medical Students 
Association (AMSA) scorecard,25 the Canadian scorecard 
by Shnier et al,26 and the French COI ranking by Scheffer et 
al.27 A list of the 38 German medical schools was obtained 
from the website of the German Medical Faculty Associ-
ation (Medizinischer Fakultätentag).28 After the formal 
exchange with a member of the German Ethics Council 
about the nature of this study, which only involves policies 
at an institutional level rather than patient data or other 
personal information, it was deemed unnecessary to ask 
for formal approval from an ethics committee.
Patient and public involvement
Neither patients nor public were involved in conceptual-
ising or conducting this study.
Web-based search
Two researchers (LS, MS) independently searched the 
websites of the respective medical schools (or if non- 
existent, the websites of the respective universities) 
using the sites’ integrated search engines in June 2018 
to identify policies related to COI, documents inter-
preting policies or material published regarding COI 
in the curriculum. Addresses of the websites searched 
are listed in online supplemental file 1. Search terms 
included ‘Interessenkonflikt’/‘Interessenskonflikt’ 
(conflict of interest), ‘Industrie’ (industry), and ‘interne 
Regulierung’ (internal regulation) based on previous 
publications.27 If a policy was in place, it was recorded 
together with the latest date of review. Only policies that 
specified their validity for medical schools were consid-
ered relevant for this study. Therefore, policies applying 
to an entire university or only to a university hospital 
were excluded. Disagreement about the inclusion of the 
recorded sources was discussed with all authors. Those 
sources included were later assessed via the methodology 
previously determined through the scoring criteria in our 
codebook (as described in the Results section, see online 
supplemental file 2).
Contacting medical schools
In May 2018, we contacted each office of the dean of medi-
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letter (see online supplemental files 3 and 4). The letter 
gave background information about the study’s purpose 
and outlined the criteria for which we needed documen-
tation. We asked the medical school to send any form of 
policy (or parts of a policy) relating to the management 
of COI, as well as information on enforcement of the 
policy. Furthermore, the letter included the request to 
provide information on curriculum contents addressing 
the consequences and management of COI. We did a 
maximum of three follow- ups for non- responders. We 
first sent an email in June 2018 reiterating the content of 
the letter previously sent. We then followed up via email 
in July 2018 and enclosed two letters of support, one from 
David Klemperer and one from Barbara Mintzes, co- au-
thor of the study which analysed COI policies at Cana-
dian medical schools and editor of a teaching manual on 
pharma promotion.29 In August 2018, we followed up by 
sending the results of the web- based search. Representa-
tives of the dean’s offices were given the opportunity to 
confirm, correct or comment on our web- based findings. 
In addition to searching the websites and contacting the 
offices of the deans of medical schools, we sought infor-
mation via personal contacts and experts in the field. 
Data cut- off was October 2018. We excluded policies from 
affiliated teaching hospitals because they are not under 
the authority of the dean of the medical school. Further, 
we excluded any policies or parts of policies that did not 
specifically apply to a medical school.
Scoring system
We adapted a scoring system based on criteria used in 
earlier studies by Scheffer et al27 and Shnier et al26 in the 
French and Canadian context, respectively, as well as 
the AMSA Scorecard.25 The following categories were 
addressed:
1. Gifts from industry.
2. Meals from industry.
3. Consulting relationships.
4. Industry- funded promotional speaking.
5. Educational activities, such as Continuing Medical 
Education (CME) lectures.
6. Participation in industry- funded promotional events.
7. Honoraria and scholarships from industry.
8. Ghostwriting and honorary authorships.
9. Industry Sales Representatives.
10. Disclosure of COI.
11. Medical school curriculum on COI.
12. Extension of policies.
13. Enforcement of policies.
Of note for category 11 ‘Medical school curriculum on 
COI’: German medical schools are not likely to implement 
policies that describe COI as an obligatory component 
of the curriculum. We accounted for this by (a) asking 
schools to provide information on curriculum contents 
addressing the consequences and management of COI 
and (b) noting curricular teaching activities identified 
via the web search. Evidence of curricular teaching was 
graded as outlined in the codebook, page 15 (see online 
supplemental file 2).
Subsequently, we graded the results for each category 
through our scoring system from 0 to 2. Generally, ‘0’ 
means no policy or a permissive policy, ‘1’ a moderate 
policy and ‘2’ a restrictive policy. Medical schools with no 
identified policy or curriculum in both survey and web- 
search were also rated with a score of 0. The translated 
codebook in English, outlining the decision pathway for 
each category is available as online supplemental file 2. 
Three reviewers (LH, TW, ST) independently undertook 
the scoring of the medical schools’ policies. All authors 
then reviewed the scoring. Any disagreement was resolved 
through discussion and majority vote. We then summed 
up the scores of all individual categories for each medical 
school to create a global score, with a range of 0–26 
points. No weighting of single categories was performed.
RESULTS
Web-based search
The web- based search on medical school’s websites was 
conducted to identify publicly available COI policies and 
evidence for curricular teaching activities addressing 
COI at German medical schools. The search yielded 
relevant results for one of the 38 medical schools: an 
anti- corruption brochure and a third- party funds statute 
from Charité-Universitätsmedizin Berlin (figure 1). 
Additional articles and publications were identified but 
excluded from analysis because they either did not relate 
to predefined criteria or did not specifically apply to the 
entire medical school. Our web- based search strategy 
revealed no information on relevant compulsory curric-
ular teaching activities addressing COI that could receive 
a score (cf. Codebook page 15, online supplemental file 
2). Only one non- compulsory elective course at Friedrich- 
Schiller- Universität Jena was identified.
Contacting medical schools
German medical schools were contacted to provide vali-
dated insight into existing COI policies. The total response 
rate was 42.1% (16 of 38). Twelve of the responding 
medical schools did not send policies. Four medical 
schools (10.5%) included policies dealing with COI, of 
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which three (an anti- corruption directive and a monetary 
benefit acceptance policy from the Ludwig- Maximilian- 
Universität München, a code of practice as well as an 
anti- corruption directive from the Julius- Maximilians- 
Universität Würzburg, a compliance brochure, gifts and 
benefits acceptance policy, and a third- party funds statute 
from the Friedrich- Schiller- Universität Jena) exclusively 
applied to university medical centres, not to the respec-
tive medical schools, and were therefore excluded from 
further analysis. One policy met inclusion criteria and 
comprised an anti- corruption directive issued by the 
medical school and university medical centre of the Tech-
nische Universität Dresden (figure 1).
See table 1 for an overview of the answers received from 
the medical schools.
Of the total of 16 replies, 5 medical schools (13.2%) 
(Universität des Saarlandes, Albert- Ludwigs- Universität 
Freiburg, Georg- August- Universität Göttingen, Christian- 
Albrechts- Universität zu Kiel, Universität Witten/
Herdecke) responded not having COI policies or that 
COI were not part of the curriculum. The Universität des 
Saarlandes stated that there was no separate policy for 
the medical school, while the Albert- Ludwigs- Universität 
Freiburg declared not having a COI policy within the 
medical curriculum, as well as no explicit lectures on 
COI. In addition, the Christian- Albrechts- Universität zu 
Kiel reported no existing COI policy within their medical 
school, neither was the topic taught in the medical curric-
ulum. The reply from the Georg- August- Universität 
Göttingen stated that basic knowledge about phar-
macoeconomics was taught, however, not mentioning 
corruption and transparency within the medical system. 
As stated by the Universität Witten/Herdecke, COI 
management lies with the contracted teaching hospitals. 
The Friedrich- Alexander- Universität Erlangen- Nürnberg 
replied that several policies apply within their university; 
however, no COI policy relevant to this study, issued by the 
medical school itself is externally available. The Univer-
sität Greifswald and the Medizinische Fakultät der Univer-
sität Hamburg initially asked for more time to reply, yet 
did not send material by the end of the data collection 
period. The Universität Augsburg was still in the process 
of setting up a medical curriculum, welcoming medical 
students starting in 2019 and was hence not able to report 
on COI policies or teaching activities. No further response 
as to whether a general COI policy existed was received. 
Table 1 Overview of the answers received from medical schools
Medical school
Response contained a policy 
meeting inclusion criteria
If applicable: response included a 
statement on curricular teaching 
activities
Medizinische Fakultät Yes NA
Carl Gustav Carus
der Technischen Universität Dresden
Universitätsmedizin Greifswald No NA
Universität Hamburg No NA
Universität des Saarlandes (Homburg) No NA
Friedrich- Schiller- Universität Jena No NA
Ludwig- Maximilians- Universität München No NA
Westfälischen Wilhelms- Universität Münster No NA
Universität Witten/Herdecke No NA
Friedrich- Alexander- Universität Erlangen- Nürnberg No NA
Goethe- Universität Frankfurt No NA
Justus- Liebig- Universität Gießen No NA
Albert- Ludwigs- Universität Freiburg No No explicit curricular teaching on COI
Georg- August- Universität Göttingen No No explicit curricular teaching on COI
Christian- Albrechts- Universität zu Kiel No No explicit curricular teaching on COI
Julius- Maximilians- Universität Würzburg No No explicit curricular teaching on COI
Universität Augsburg No NA
The schools not mentioned in the table did not reply to any of our three emails sent. Those are: Universität Augsburg, RWTH Aachen, 
Charité—Universitätsmedizin Berlin, Ruhr- Universität Bochum, Rheinischen Friedrich- Wilhelms- Universität Bonn, Universität Duisburg- Essen, 
Heinrich- Heine- Universität Düsseldorf, Martin- Luther- Universität Halle- Wittenberg, Medizinische Hochschule Hannover, Ruprecht- Karls- 
Universität Heidelberg, Universität zu Köln, Universität Leipzig, Universität zu Lübeck, Otto- von- Guericke- Universität Magdeburg, Johannes- 
Gutenberg- Universität Mainz, Medizinische Fakultät Mannheim der Ruprecht- Karls- Universität Heidelberg, Philipps- Universität Marburg, 
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The Westfälische- Wilhelms- Universität Münster and the 
Goethe- Universität Frankfurt reported no capacities to 
take part in our study, while the Justus- Liebig- Universität 
Gießen actively decided against participating. The Univer-
sität Ulm addressed neither COI policies nor curriculum 
contents in their reply. The remaining medical schools 
did not respond to any request during the data acquisi-
tion period.
Analysis of COI policies
The two included policies were assessed according to a 
predefined scoring system as set out in our codebook (see 
online supplemental file 2). Results of each analysis are 
listed in figure 2.
With 12 out of 26 points, the Technische Universität 
Dresden achieved the highest score. Charité Universi-
tätsmedizin Berlin scored four points in total. All other 
medical schools did not supply a valid COI policy and 
had no retrievable information on COI policies on their 
websites according to inclusion criteria (figure 1).
We did not acquire any information about obligatory 
teaching activities on COI through web- based search or 
the deans’ survey. However, through personal contacts 
and seeking advice from experts, we received informa-
tion on courses that cover COI at three medical schools 
(7.9%): Charité Universitätsmedizin Berlin, Universität 
Mainz and Universität Leipzig. These teaching activities 
are either lectures in which COI is discussed (Universität 
Leipzig, Universität Mainz, Charité Universitätsmedizin 
Berlin) or elective courses that students can choose 
within their curriculum (Charité Universitätsmedizin 
Berlin, Universität Mainz).
DISCUSSION
Statement of principal findings
In this cross- sectional study and survey of German 
medical schools, we found that only two German medical 
schools (5.3%) have policies relating to COI in place. 
Moreover, none of these policies sufficiently covered the 
broad spectrum of evaluated categories with relevance 
to COI, nor did they focus explicitly on the context of 
medical education. No medical school reported curric-
ular teaching on COI. The maximum score achieved was 
12 of 26. 36 (94.7%) schools were rated with a score of 0. 
Those also included non- responders to the survey without 
discoverable policies in the web- search (22 schools, 61%). 
These results indicate little effort by German medical 
schools to address the issue of COI in medical education.
Strengths and limitations of the study
In total, 16 out of 38 medical schools responded to our 
letter and emails, and therefore, COI teaching activities 
and policies by non- responding medical schools may 
have been missed. To address this issue, we conducted 
a systematic web- search, which in general supported the 
results of the survey. The policy identified for Charité 
Universitätsmedizin Berlin was evaluated without a 
response from the dean’s office to validate the docu-
ment retrieved online. The web- search was performed 
with few predefined search terms using integrated 
search engines on the websites of medical schools, 
thus limiting potentially retrievable documents. Conse-
quently, the results of this study might underestimate 
the number of COI policies and teaching activities that 
are publicly available. However, scarce results among the 
16 medicals schools participating in the survey as well 
as from the web- search indicate that too few German 
medical schools adopted policies on COI and educate 
their students about COI.
Medical schools do not exist in a vacuum, and further 
COI policies may exist at a university- wide level or at 
university medical centres. We argue that the conse-
quences of COI in medicine potentially harm patient 
health and are, therefore, even more critical compared 
with COI that might occur in other fields. Thus, medical 
schools require more restrictive COI policies than other 
departments within a university. Teaching physicians are 
predominantly also employed by a university medical 
centre which might issue COI policies not specifically 
applying to their affiliated medical school. However, 
these policies are aimed at COI of physicians working 
in patient care and lack specific regulations that apply 
to the teaching environment of medical students. It 
predominantly lies within the capacity of teaching faculty 
at medical schools to introduce core knowledge on COI 
in the classroom. In this study, teaching on COI contrib-
uted to the overall score as one of 13 categories. This 
might underrepresent the importance of teaching activ-
ities within the efforts of medical schools to address COI 
during medical studies.
Figure 2 Overview of strength of the two COI policies included. empty circle=permissive/no policy (score=0), half- circle: 
moderate policy (score=1), full circle=restrictive policy (score=2). Criteria were prespecified in the codebook (see online 
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Strengths and limitations in relation to other studies, 
discussing important differences in results
Comparable studies were conducted in USA, Canada, 
Australia and France, allowing for an international 
comparison of our results.25–27 30 In general, North Amer-
ican medical schools tackle the issue of COI in medical 
education more proactively. In Canada 16 of 17 medical 
schools had some form of COI policy in place in 201326 
and in 2014, 136/160 US medical schools reported an 
existing policy on COI.25 The Australian study found 
that 7 medical schools out of 20 had a COI policy.30 The 
French study exposed similar results as our own data. 
They found no formal COI policy at any of the 37 French 
medical schools and only scattered COI teaching activi-
ties. Their response rate of 8.1% may be indicative of the 
low interest in the topic by medical schools at this time. 
The publication of these results led to increased media 
attention,31 and ultimately, the French deans’ conference 
adopted a nation- wide COI policy.32
The best performing policy in our study was an anti- 
corruption directive issued by the Technische Universität 
Dresden that included four restrictive and four moderate 
elements related to different scoring categories. Yet we 
were unable to retrieve this policy from the medical 
school’s website during the performed web- search. Prior 
studies excluded non- public policies from analysis, since 
an inaccessible, not widely circulated policy is unlikely 
to have a relevant impact and may go unrecognised 
by academic staff.26 30 In an earlier study, two German 
medical schools were reported to have a policy on COI.20 
Our research could only verify one of those COI policy 
equivalents at TU Dresden. RWTH Aachen reported 
a policy in 2014 but did not reply to our study, nor was 
a policy identified on the school’s website. Despite six 
medical schools committed to the development of a COI 
policy in 2014,20 our results indicate that no policy has 
been published since. Furthermore, we did not receive 
any information about teaching on COI through the 
deans’ survey. This is in contrast to the survey by Lieb 
and Koch.20 In their study, deans from seven medical 
schools reported COI teaching activities (Universität 
Bonn, Universität Erlangen- Nürnberg, Universität des 
Saarlandes (Homburg), Universität Gießen, Universität 
Göttingen, Universität Frankfurt, Universität Köln). 
From these medical schools, only the dean’s office of 
Universität Göttingen commented on COI teaching and 
declared that their curriculum included basic education 
on pharmacoeconomics but did not explicitly cover COI 
related aspects like transparency or corruption.
Implications for medical schools and policymakers
Education and policies on COI have been suggested 
to sensitise medical students in favour of the indepen-
dence of medical education from undue industry influ-
ence.4 22–24 Medical students themselves increasingly 
demand stronger COI regulations, disclosure of teaching 
faculty’s COI and courses on COI. The German Medical 
Students’ Association (bvmd e.V.) adopted a position 
paper on the independence of education in 2013.33 In May 
2019 the European Medical Students Association passed 
a policy titled ‘Conflicts of Interest in Medical Educa-
tion Settings’34 and the International Medical Students’ 
Association followed in August 2019 with a policy called 
‘Integrity and transparency in medical education’.35 
These actions are indicative of broader student interest 
in policy change.
We found COI teaching activity at German medical 
schools, if existent, to be an initiative by singular faculty 
members rather than a structured component of the 
curriculum. Those mostly encompassed elective courses 
or singular lectures that are not available to all students 
and hence received no score. The scarce efforts to include 
COI in teaching are all the more surprising, since the 
German National Competence- Based Learning Objec-
tives for Undergraduate Medical Education include COI 
(without specifically naming them) in chapter 11.1.1.2.36 
Moreover, the "Institut für medizinische und pharmaze-
utische Prüfungsfragen" (IMPP, institute for medical and 
pharmaceutical examination questions) that develops 
national exams for medical students in Germany intro-
duced an item directly referring to COI in its latest edition 
published in November 2019. Recently, a randomised 
controlled trial showed that a structured and integrated 
curriculum on COI and risk communication leads to a 
large and sustainable increase in risk communication 
performance among German medical students.37 Taking 
the mounting evidence, broad student engagement and 
changing requirements into consideration, German 
medical schools are under pressure to adopt structured 
COI curricula and policies that are mandatory to all 
students and form part of a core curriculum.
Unanswered questions and future research
In the US, the regular AMSA scorecard assessed COI poli-
cies at US medical schools until 2016 and contributed to 
a constant improvement in policies since its initiation in 
2007.25 Regular evaluation of the development of poli-
cies and curricula addressing COI might also be useful 
in Germany to incentivise and monitor progress towards 
better COI education at medical schools.
Policy development is a dynamic process and some 
schools signalled willingness to introduce teaching activi-
ties and considered COI policies after we contacted them. 
This, however, was also the case in previous studies.20 
Yet, our work indicates that little action was taken since 
then. Future research should further assess the impact of 
stringent policies during medical training on prescribing 
behaviour, and ultimately evaluate other patient relevant 
outcomes.
CONCLUSION
In contrast to other parts of the world, such as North 
America, German medical schools barely regulate 
students’ contact with pharmaceutical companies or 
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and increasingly students themselves are demanding a 
cultural change in the medical profession starting with 
independent, unbiased medical education.33–35 COI poli-
cies at medical schools have been shown to positively 
impact prescribing and practise.22–24 Medical schools in 
Germany have a key responsibility to protect students 
from undue influence and enable them to critically 
appraise information to achieve the best possible patient 
care. Although national learning objectives include 
teaching on COI, German medical schools do too little 
and have a long way to go.
Twitter Peter Grabitz @PeterRolandG
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